Efficacy of perampanel in a patient with epilepsia partialis continua

Publication date: Available online 27 September 2017 Source:Epilepsy & Behavior Case Reports Author(s): H. Argente-Escrig, A. Gómez-Ibáñez, V. Villanueva Perampanel is the first-in-class selective and noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist. It is authorized in the US and Europe as an add-on antiepileptic drug for partial-onset seizures, and for primary generalized tonic-clonic seizures. Single reports have also indicated a potential efficacy on myoclonic jerks. Here, we report a patient whose refractory epilepsia partialis continua completely resolved after adding perampanel. She has remained seizure-free in an eighteen-month follow-up period. Epilepsia partialis continua reemerged transiently after perampanel was temporarily discontinued, with no recurrence after its reintroduction. Therefore, this effect was reproducible, and suggests that it might be worth trying perampanel in similar settings.

Source: Epilepsy and Behavior Case Reports - September 28, 2017 Category: Neurology Source Type: research